Meta Financial Group (NASDAQ:CASH) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.71 by 14.08 percent. This is a 62 percent increase over earnings of $0.50 per share from the same period last year.
AstraZeneca Announced Enhertu Approved In China As The First HER2-Directed Therapy For Patients With HER2-Low Metastatic Breast Cancer
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-)
